Evidence map›Paper›PMID 35486908›Full record

ArticleCancer communications (London, England)2022

ZBED2 expression enhances interferon signaling and predicts better survival of estrogen receptor-negative breast cancer patients.

Dingxie Liu, Qiongyu Hao, Jieqing Li, Qun Li, Kun Wang, Qing Geng, Yutong Wu, Jaydutt V Vadgama, Yong Wu

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Dingxie LiuBluewater Biotech LLC, New Providence, NJ, 07974, USA.
Qiongyu HaoDivision of Cancer Research and Training, Department of Internal Medicine, Charles Drew University of Medicine and Science, David Geffen UCLA School of Medicine and UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, 90095, USA.ORCID 0000-0002-4720-767X
Jieqing LiDivision of Cancer Research and Training, Department of Internal Medicine, Charles Drew University of Medicine and Science, David Geffen UCLA School of Medicine and UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, 90095, USA.
Qun LiDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200123, P. R. China.
Kun WangDepartment of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, P. R. China.
Qing GengDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P. R. China.
Yutong WuBluewater Biotech LLC, New Providence, NJ, 07974, USA.
Jaydutt V VadgamaDivision of Cancer Research and Training, Department of Internal Medicine, Charles Drew University of Medicine and Science, David Geffen UCLA School of Medicine and UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, 90095, USA.
Yong WuDivision of Cancer Research and Training, Department of Internal Medicine, Charles Drew University of Medicine and Science, David Geffen UCLA School of Medicine and UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, 90095, USA.ORCID 0000-0002-1698-0897
UCLA Health · USProvidence College · USGuangdong Academy of Medical Sciences · CNTongji University · CNWuhan University · CN

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Workshop for Junior Biostatisticians in Health ResearchU54MD007598 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI Ali Andalibi, Jose A Torres-Ruiz · 2012 to 2026
$60.0M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Supporting African American Churches to Promote Cancer ScreeningU54CA143931 · NCI · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI VADGAMA, JAYDUTT V. · 2009 to 2022
$19.7M
RESEARCH INFORMATICS COREG12RR003026 · NCRR · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI BAKER, RICHARD S. · 1986 to 2004
$11.5M
Training and Mentoring ProgramsU54CA143930 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PIETRAS, RICHARD JOSEPH · 2009 to 2020
$7.5M
A novel metabolic reprograming strategy for the treatment of diabetes-associated breast cancerSC1GM135050 · NIGMS · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI WU, YONG · 2020 to 2023
$1.4M
Mechanisms behind hyperglycemia-associated breast cancer risk and progressionSC1CA200517 · NCI · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI WU, YONG · 2015 to 2018
$1.4M
Drew/UCLA Cancer Partnership ProgramU56CA101599 · NCI · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI VADGAMA, JAYDUTT V. · 2003 to 2009
$1.3M
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NCI NIH HHS SC1 CA200517NCI NIH HHS U54 CA143930NCI NIH HHS U54 CA143931NCI NIH HHS U56 CA101599NCRR NIH HHS G12 RR003026NIGMS NIH HHS SC1 GM135050NIMHD NIH HHS U54 MD007598
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsTriple Negative Breast NeoplasmsCell Line, TumorDisease-Free SurvivalFemaleHumansInterferonsReceptors, EstrogenInterferonsReceptors, Estrogen

Identifiers

PMID35486908
PMCPMC9257990
OpenAlexW4225088434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.